Industry Analysis & Industry Trends
On the mend
The Anti-Fungal Medication OTC industry managed to perform well during the recession, as lower rates of insurance spurred demand for less-expensive treatments. Further, demand from consumers who self-diagnosed themselves has benefited the industry, since individuals often purchase products that they do not need. Revenue will continue to grow, despite higher rates of insurance, as the population ages and firms invest in R&D.... purchase to read more
Industry Report - Starting a New Business Chapter
There are high initial costs to producing OTC anti-fungal medications. Costs include financial outlays for machinery, research and development, and the time that it takes to gain FDA approval for OTC drugs. The patent system can also be a barrier to entry into the industry. A significant initial investment that companies must make is in machinery. This industry's production is mostly automated, resulting in high capital intensity. Moderate developments in production technologies also indicate a higher initial investment in machinery because new companies will not be as likely to use older (cheaper) models of machines.
Regulation
A significant cost for the industry involves the time that it takes to gain approval to sell OTC. As... purchase to read more